		<div class="wpcnt">
			<div class="wpa">
				<span class="wpa-about">Advertisements</span>
				<div class="u top_amp">
							<amp-ad width="300" height="265"
		 type="pubmine"
		 data-siteid="111265417"
		 data-section="2">
		</amp-ad>
				</div>
			</div>
		</div><p>An experimental drug designed to lower cholesterol may turn out to be an effective weapon against prostate cancer, research has shown.</p>
<p>Tumour cells need cholesterol to construct their cell membranes. By cutting their cholesterol production, the new molecule, known as RO 48-8071, causes the cells to fall apart and die.</p>
<p>It could also have the added benefit of preventing prostate cancer developing resistance to hormone therapies.</p>
<p>Professor Salman Hyder, from the University of Missouri in the US, said: &#8220;Cholesterol is a molecule found in animal cells that serves as a structural component of cell membranes. When tumour cells grow, they synthesise more cholesterol.</p>
<p>&#8220;Often, cancer patients are treated with toxic chemotherapies; however, in our study, we focused on reducing the production of cholesterol in cancer cells, which could kill cancer cells and reduce the need for toxic chemotherapy.&#8221;</p>
<p>The compound was originally developed by the drug company Roche for the treatment of high cholesterol.</p>
<p>Prof. Hyder&#8217;s team found that human prostate cancer cells exposed to the drug in the laboratory died.</p>
<p>When the drug was injected into mice with human prostate cancer, tumour growth was curbed.</p>
<p>Importantly, the drug appeared to be effective against prostate cancer cells that had become resistant to hormone treatments.</p>
<p>Prostate cancer is initially tackled by preventing its growth being fuelled by the male hormone testosterone. But over time, the cancer stops responding to this treatment.</p>
<p>One way tumours ensure their survival is by manufacturing their own testosterone through a process that relies on cholesterol.</p>
<p>&#8220;Cholesterol &#8230; can contribute to the development of anti-hormone resistance because cholesterol is converted into hormones in tumour cells,&#8221; said Prof Hyder. &#8220;Therefore, these cholesterol-forming pathways are attractive therapeutic targets for the treatment of prostate cancer.&#8221;</p>
<p>The study is due to appear in the journal OncoTargets and Therapy.</p>
			<div style="padding-bottom:15px;" class="wordads-tag" data-slot-type="belowpost">
				<div id="atatags-dynamic-belowpost-68ed4181c55d4">
					<script type="text/javascript">
						window.getAdSnippetCallback = function () {
							if ( false === ( window.isWatlV1 ?? false ) ) {
								// Use Aditude scripts.
								window.tudeMappings = window.tudeMappings || [];
								window.tudeMappings.push( {
									divId: 'atatags-dynamic-belowpost-68ed4181c55d4',
									format: 'belowpost',
								} );
							}
						}

						if ( document.readyState === 'loading' ) {
							document.addEventListener( 'DOMContentLoaded', window.getAdSnippetCallback );
						} else {
							window.getAdSnippetCallback();
						}
					</script>
				</div>
			</div>
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
